-
Endpoints News3 months ago
Pfizer’s Lyme disease vaccine trial hampered by lack of cases
Pfizer’s final-stage trial of its long-awaited Lyme disease vaccine missed its primary endpoint, but the drugmaker said it still plans to try to take the experimental...
-
STAT News – Biotech3 months agoSTAT+: Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle
An experimental vaccine from Pfizer and Valneva reduced the risk of developing Lyme disease by more than 70%, according to newly released data. Though results appear...
-
STAT News – Biotech3 months agoSTAT+: Apogee Therapeutics data show long-acting eczema drug induced relief with less frequent injections
An experimental, long-acting treatment for eczema from Apogee Therapeutics induced skin and itch relief comparable to current, widely used medicines but with less frequent injections, a...
-
Fierce Biotech3 months ago
Stryker continues to bring hacked systems back online after patients delay surgeries
Stryker said its manufacturing capacity is ramping up quickly as plants are brought back online as well as electronic ordering and shipping.
-
Uncategorized3 months agoIsomAb appoints CEO to lead development of angina treatment
Biotechnology company IsomAb has appointed Dr Philip Brainin as Chief Executive Officer as it looks to enter clinic with a treatment for chronic stable angina (CSA). ...
-
Fierce Biotech3 months ago
Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D
Novartis is investing more than 3.3 billion Chinese yuan (roughly $480 million) to soup up its manufacturing facility in Beijing and strengthen its R&D campus in...
-
Uncategorized3 months agoClot-busting drug could harm stroke treatment response
A clot-busting drug may stop promising stroke medicine from working properly, research reveals. Researchers at the University of Manchester found the clot-busting therapy, known as tissue...
-
Fierce Biotech3 months ago
Apogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clear
Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, Regeneron and Sanofi, prompting analysts to double...
-
BioPharma Dive – AI / Data3 months ago
Risk, readiness and resilience
The location secret behind pharma’s most reliable East Coast expansion corridor.
-
Fierce Biotech3 months ago
FDA solicits feedback on controversial national priority voucher review pathway
The FDA has scheduled a public hearing for June 12 to hear input on the Commissioner’s National Priority Voucher program, which it introduced last June. So...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
